These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36916077)

  • 21. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database.
    Benevent J; Araujo M; Karki S; Delarue-Hurault C; Waser J; Lacroix I; Tebeka S; Damase-Michel C
    J Clin Psychiatry; 2023 Jul; 84(4):. PubMed ID: 37437238
    [No Abstract]   [Full Text] [Related]  

  • 22. Selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors in pregnancy: Infant and childhood outcomes.
    Hendson L; Shah V; Trkulja S
    Paediatr Child Health; 2021 Aug; 26(5):321-322. PubMed ID: 34336063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of antidepressants in pregnancy: focus on maternal risks.
    Gadot Y; Koren G
    J Obstet Gynaecol Can; 2015 Jan; 37(1):56-63. PubMed ID: 25764038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of adverse events and comparative tolerability of selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for the treatment of anxiety, obsessive-compulsive, and stress disorders: a systematic review and network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Frozi J; Spanemberg L; Manfro GG; Cortese S; Cuijpers P; Pine DS; Salum GA
    Psychol Med; 2023 Jul; 53(9):3783-3792. PubMed ID: 37278215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events.
    Lee YC; Lin CH; Lin MS; Lu Y; Chang CH; Lin JW
    J Clin Psychiatry; 2016 Jan; 77(1):e1-7. PubMed ID: 26845272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines.
    Mendez EM; Mills JA; Suresh V; Stimpfl JN; Strawn JR
    CNS Spectr; 2024 Jun; 29(3):187-196. PubMed ID: 38523533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis.
    Tan B; Chen L; Yan S; Pan H; Zhang J; Wei H
    Sci Rep; 2024 Jul; 14(1):15167. PubMed ID: 38956425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affective disorders.
    Colombo A; Giordano F; Giorgetti F; Di Bernardo I; Bosi MF; Varinelli A; Cafaro R; Pileri P; Cetin I; Clementi E; Viganò CA; Dell'Osso B
    Hum Psychopharmacol; 2021 May; 36(3):e2772. PubMed ID: 33253437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?
    Ornoy A; Koren G
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31091646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders.
    Jakubovski E; Johnson JA; Nasir M; Müller-Vahl K; Bloch MH
    Depress Anxiety; 2019 Mar; 36(3):198-212. PubMed ID: 30479005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials.
    Azizi M; Khani S; Kamali M; Elyasi F
    Iran J Med Sci; 2022 May; 47(3):173-193. PubMed ID: 35634530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin-norepinephrine reuptake inhibitor antidepressants and the risk of falls in older people: case-control and case-series analysis of a large UK primary care database.
    Gribbin J; Hubbard R; Gladman J; Smith C; Lewis S
    Drugs Aging; 2011 Nov; 28(11):895-902. PubMed ID: 22054230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
    Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
    Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data.
    Singal D; Brownell M; Chateau D; Ruth C; Katz LY
    BMJ Open; 2016 Nov; 6(11):e013293. PubMed ID: 27899401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths.
    Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL
    JAMA Pediatr; 2017 Dec; 171(12):1200-1207. PubMed ID: 29049533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.
    Renoux C; Lix LM; Patenaude V; Bresee LC; Paterson JM; Lafrance JP; Tamim H; Mahmud SM; Alsabbagh MW; Hemmelgarn B; Dormuth CR; Ernst P;
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1716-22. PubMed ID: 26231193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor Use as a Predictor of a Diagnosis of Restless Legs Syndrome.
    Bailey AL; Makela EH; Asberg K
    J Psychiatr Pract; 2016 Jul; 22(4):263-9. PubMed ID: 27427838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review.
    Bellantuono C; Vargas M; Mandarelli G; Nardi B; Martini MG
    Hum Psychopharmacol; 2015 May; 30(3):143-51. PubMed ID: 25784291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.